Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization.

about

Angiogenesis and lymphangiogenesis in corneal transplantation-A review.Vascular Endothelial Growth Factor (VEGF) Serological and Lacrimal Signaling in Patients Affected by Vernal Keratoconjunctivitis (VKC)

P2860

Q47759308-86E0A597-3D12-4318-8D52-60530D5D37F4 Q57300310-750CD420-5182-4E6B-89B8-BF59E99516FB

P2860

Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization.

Item

http://www.wikidata.org/entity/Q38755418

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Topical versus subconjunctival ...... of corneal neovascularization.

@en

type

Item

label

Topical versus subconjunctival ...... of corneal neovascularization.

@en

prefLabel

Topical versus subconjunctival ...... of corneal neovascularization.

@en

P1476

Topical versus subconjunctival ...... of corneal neovascularization.

@en

P2093

Abdulkareem Al-Bekairy

http://www.w3.org/2001/XMLSchema#string

Abdulmalik Al-Katheri

http://www.w3.org/2001/XMLSchema#string

Mahmoud Mansour

http://www.w3.org/2001/XMLSchema#string

Shmeylan Al Harbi

http://www.w3.org/2001/XMLSchema#string

Tariq Al-Debasi

http://www.w3.org/2001/XMLSchema#string

P2860

Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen

Corneal neovascularization. Pathogenesis and inhibition

Corneal avascularity is due to soluble VEGF receptor-1

Corneal neovascularization.

Inhibition of corneal neovascularization after alkali burn: comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone.

Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival

Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis.

Management of alkali burns : an 11-year retrospective review.

Ocular immune privilege: therapeutic opportunities from an experiment of nature.

Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization.

P304

99-105

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.SJOPT.2017.02.008

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28559722

http://www.w3.org/2001/XMLSchema#string

P921

endothelium

neovascularization

bevacizumab

P932

5436388

http://www.w3.org/2001/XMLSchema#string

Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization.

about

P2860

P2860

Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932